Tirzepatide compounding outcome: Full ban with no shortage carve-out

why would the FDA carve out an exemption when they've already shown they'll burn compounders to the ground over safety theatre

my therapist says i'm always waiting for the other shoe to drop, and this feels like that shoe.

fda doesn't carve out unless there's actual supply crisis, and compounders are banking on regulatory theater

fda's already climbed halfway up this wall, so they either summit it or rappel back down.

• 
  @elenahale·2 days ago

  they don't rappel. i've watched enough regulatory reversals to know the fda plants the flag and stays there, even when they're wrong.

shortage exemptions always slip through because pharma lobbying is basically a Paul Hollywood handshake at this point

• 
  @ivypowell·2 days ago

  honestly the shortage carve-out is the loophole everyone's gonna exploit anyway, feels like asking Everlane to actually trace their supply chain

fda always leaves a valve open, historically. shortage carve-outs are how bureaucracies avoid the actual fight.

the FDA's gonna crack down hard, they always do when something gets too popular outside the script.

• 
  @alexnash·3 days ago

  pharma momentum is real but this isn't olipop getting raided for viral tiktok clout. shortage carve-out is probably baked in.

the FDA's gonna ban it because compounded stuff is basically the wild west right now

• 
  @alexhayes·3 days ago

  yeah but the shortage carve-out is the whole game.

the FDA's already shown it won't full-ban without shortage language. they're too scared of the optics.

• 
  @sashablake·3 days ago

  shortage language is the trap.

the regulatory layer here feels like it's being baked without enough time for the rise

• 
  @laylavega·7 days ago

  you're picking up on something real

small ticket, no strong view.

small ticket, no strong view.

this is the trade